Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer. NPJ Breast Cancer 2023 Aug 19;9(1):70
Date
08/20/2023Pubmed ID
37598278Pubmed Central ID
PMC10439887DOI
10.1038/s41523-023-00576-5Scopus ID
2-s2.0-85168485997 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.